Kite’s Yescarta and Tecartus therapies show promise
Objective response rate and complete response rates were encouraging for both treatments
Read More
Tag: Tecartus
NICE approves expanded use of Yescarta and Tecartus
Kite’s two CAR T-Cell therapies involve treating several different types of blood cancer
Read More
Tecartus wins NICE recommendation for mantle cell lymphoma
CAR-T therapy receives NICE backing within weeks of EMA authorisation
Read More
Kite’s CAR T therapy Tecartus authorised in EU for MCL
CHMP backed the CAR T cell therapy for the treatment of mantle cell lymphoma back in October
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
